аналіз неХірУргічниХ, УсКладнень У паЦієнтів, з імплантОваними, пристрОями меХанічнОї підтримКи, лівОгО ШлУнОчКа, мазуренко О.п, надзякевич п, лоскутов О.а, згржебловська л.в
{"title":"Analysis of non-surgical complications in patients with implanted mechanical support devices for the left ventricle","authors":"аналіз неХірУргічниХ, УсКладнень У паЦієнтів, з імплантОваними, пристрОями меХанічнОї підтримКи, лівОгО ШлУнОчКа, мазуренко О.п, надзякевич п, лоскутов О.а, згржебловська л.в","doi":"10.25284/2519-2078.4(89).2019.187827","DOIUrl":null,"url":null,"abstract":"The work was performed within the framework of a bilateral agreement on scientific cooperation between the NMAPE named P.L. Shupyk (Department of Anesthesiology & Intensive Care) and the Silesian Center for Heart Disease (Poland).Resume. The work is devoted to the study of infectious, nephrotic, neurological, pulmonary aortic, right ventricle and other complications in the early postoperative period in ten patients with implanted left ventricle assist devices (LVAD). The most common non-surgical complications include infections, ischemic-hemorrhagic lesions of the brain that arise in the postoperative period of acute renal failure. Conducting optimal antithrombotic therapy in such patients is an important method of treatment, especially in the early postoperative period. Most of the infectious complications develop in the exit places of the power cable of the implanted devices. An individual approach to preventive strategies is critical to improving patient outcomes. This article presents an analysis of complications that developed in the early postoperative period in ten patients with LVAD implanted devices in the Silesian Center for Heart Disease (SCCS), Poland. Patients were divided into two groups in the control group receiving classical anticoagulant targeted therapy (ATT), which included heparin, varfarin and aspirin and the subjects receiving an alternative ATT, that consisted of cropidogrel, thrombin inhibitors in combination with classical anticoagulant target therapy.","PeriodicalId":355172,"journal":{"name":"Pain, Anaesthesia and Intensive Care","volume":"22 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain, Anaesthesia and Intensive Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25284/2519-2078.4(89).2019.187827","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The work was performed within the framework of a bilateral agreement on scientific cooperation between the NMAPE named P.L. Shupyk (Department of Anesthesiology & Intensive Care) and the Silesian Center for Heart Disease (Poland).Resume. The work is devoted to the study of infectious, nephrotic, neurological, pulmonary aortic, right ventricle and other complications in the early postoperative period in ten patients with implanted left ventricle assist devices (LVAD). The most common non-surgical complications include infections, ischemic-hemorrhagic lesions of the brain that arise in the postoperative period of acute renal failure. Conducting optimal antithrombotic therapy in such patients is an important method of treatment, especially in the early postoperative period. Most of the infectious complications develop in the exit places of the power cable of the implanted devices. An individual approach to preventive strategies is critical to improving patient outcomes. This article presents an analysis of complications that developed in the early postoperative period in ten patients with LVAD implanted devices in the Silesian Center for Heart Disease (SCCS), Poland. Patients were divided into two groups in the control group receiving classical anticoagulant targeted therapy (ATT), which included heparin, varfarin and aspirin and the subjects receiving an alternative ATT, that consisted of cropidogrel, thrombin inhibitors in combination with classical anticoagulant target therapy.